[DOI] [PMC free article] [PubMed] [Google Scholar] 155.Farmer A.D., Ban V.F., Coen S.J., Sanger G.J., Barker G.J., Gresty M.A., Giampietro V.P., Williams S.C., Webb D.L., Hellstrm P.M., et al
The European Centre for Disease Prevention and Control (ECDC) reports that chronic diseases account for over 80% of healthcare burden in Europe, while multiple EU countries have expanded reimbursement frameworks, improving access to innovative therapies like GLP-1 receptor agonists
Tirzepatide: MEDVi Launches Physician-Led Program to Help Patien MEDVi, a telehealth platform serving more than 100,000 patients, today announced an expanded physician-led program designed to help patients navigate the decision between semaglutide and tirzepatide, two GLP-1 medications at the center of the weight loss conversation in 2026 Image: Disclosure: This announcement is for informational purposes only and does not constitute medical advice
Along with prompting insulin production to lower blood sugar levels, GLP-1 interacts with the brain to regulate appetite and induce a feeling of fullness
